CLOT refers to the Randomized Comparison of Low-Molecular-Weight Heparin
versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT).
should be the drug of choice for the initial treatment of deep vein thrombosis in cancer patients, according to new management recommendations developed by the National Comprehensive Cancer Network.
Patients with factor V Leiden mutations who've received low-molecular-weight heparin
within 12 hours of labor onset should take a heparin test before undergoing neuraxial anesthesia.
and unfractionated heparin were used most often.
The primary objective of the study is to assess the predictive value of the ENOX test to measure the whole blood anticoagulant effect of the low-molecular-weight heparin
enoxaparin relative to ischemic and hemorrhagic outcomes associated with PCI.
1 selling low-molecular-weight heparin
in the world, Lovenox(R) is obtained by alkaline degradation of heparin benzyl ester and is about one-third the molecular size of unfractionated heparin.
NEW ORLEANS -- Antithrombotic treatment, in the form of the low-molecular-weight heparin
reviparin, has been shown for the first time to safely improve outcomes after acute myocardial infarction.
Aventis, which manufactures the low-molecular-weight heparin
(LMWH), sent a letter to health care professionals in February about additions to the drug's labeling information.
The patient responded to corticosteroids, low-molecular-weight heparin
, clindamycin, and azathioprine therapy, they said.
Outpatient management with a low-molecular-weight heparin
is the wave of the future for treating deep vein thrombosis.
With 1999 worldwide sales exceeding $780 million, enoxaparin is the number-one selling low-molecular-weight heparin
(LMWH) in the world.
1-selling low-molecular-weight heparin
in the world, Lovenox(R) was approved in the United States and Canada in 1993.